We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.


1 December 2003 By Robert Cyran

Pfizer has dropped its right to sell Celltech’s arthritis drug. With a majority of Celltech s value tied up in this one drug and new drugs hard to find the company may find suitors knocking.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)